Screening for tuberculosis infection prior to initiation of anti-TNF therapy
2008

Screening for Tuberculosis Before Anti-TNF Therapy

Sample size: 142 publication Evidence: moderate

Author Information

Author(s): Ajit Lalvani, Kerry A. Millington

Primary Institution: Imperial College London

Hypothesis

The study investigates the effectiveness of T-cell interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) for diagnosing latent tuberculosis infection (LTBI) in patients with immune-mediated inflammatory diseases (IMID) prior to anti-TNF therapy.

Conclusion

IGRAs are more specific and probably more sensitive than TST for diagnosing LTBI in patients with IMID who are candidates for anti-TNF therapy.

Supporting Evidence

  • IGRAs are more closely associated with risk factors for LTBI than TST.
  • The proportion of TST-positive results is significantly lower in patients with IMID compared to healthy controls.
  • Discordant TST-positive, IGRA-negative results are linked to prior BCG vaccination.
  • Discordant TST-negative, IGRA-positive results are associated with steroid therapy.

Takeaway

Doctors need to check for tuberculosis in patients starting certain treatments because those treatments can make tuberculosis more dangerous. New blood tests are better at finding tuberculosis than the old skin test.

Methodology

The study reviews the performance of IGRAs in diagnosing LTBI in patients with IMID, comparing results with TST and assessing associations with risk factors for LTBI.

Potential Biases

Potential biases may arise from the small sample sizes and the reliance on existing studies with varying methodologies.

Limitations

The evidence base for IGRA performance in patients on anti-TNF therapy is limited and requires further longitudinal studies.

Participant Demographics

Participants included patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.

Statistical Information

P-Value

p<0.01

Confidence Interval

95% CI 5.14 to 110

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1016/j.autrev.2008.07.011

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication